Immune-Mediated Necrotizing Myopathy: An Often Misdiagnosed Entity by Espírito Santo, Joana Almeida et al.
 	  
Doi:	  10.12890/2015_000164	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   European	  Journal	  of	  Case	  Reports	  in	  Internal	  Medicine	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   ©	  EFIM	  2015	  
Immune-­‐Mediated	  Necrotizing	  Myopathy:	  An	  Often	  Misdiagnosed	  Entity	  
	  
Joana	  Espírito	  Santo	  a,	  Rui	  Garciaa,	  Benilde	  Barbosaa,	  Olinda	  Rebelob,	  José	  Pereira	  de	  Mouraa	   	  
a	  Internal	  Medicine	  Department	  A,	  University	  Hospital	  Center	  of	  Coimbra,	  Coimbra,	  Portugal	  




Immune-­‐mediated	  necrotizing	  myopathies	  (IMNM)	  are	  recognized	  as	  a	  subgroup	  of	  idiopathic	  inflammatory	  myopathies	  
(IIM).	   IMNM	  are	   defined	   based	   on	   a	   combination	   of	   clinical	   presentation	   and	   laboratory	   studies,	   requiring	   a	   specific	  
myopathological	   pattern	   on	   muscle	   biopsy	   for	   diagnosis.	   The	   authors	   describe	   a	   case	   of	   a	   patient	   with	   necrotizing	  
myopathy,	   thought	   to	   be	   immune	   mediated,	   highlighting	   the	   challenge	   of	   its	   differential	   diagnosis.	   As	   clinical	  
assessment	   and	   diagnostic	   tools	   sometimes	   fail	   to	   determine	  whether	   a	   necrotizing	  myopathy	   is	   immune	  mediated,	  
leading	   to	  misdiagnosis	   and	   a	   compromise	   of	   the	   optimal	   therapeutic	   approach,	   distinguishing	   between	   IMNM	   and	  
other	  myopathies	  is	  crucial.	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Introduction	  
Myopathy	  defines	  a	  muscle	  disease	  that	  can	  be	  inherited	  or	  acquired.	   Idiopathic	   inflammatory	  myopathies	  (IIM)	  are	  a	  
heterogeneous	   set	   of	   acquired	  muscle	   disorders.	  Distinct	   categories	   have	  been	  proposed	  based	  on	   a	   combination	  of	  
clinical	   presentation,	   laboratory	   studies	   and	   pathological	   findings	   in	   muscle	   biopsy:	   polymyositis,	   dermatomyositis,	  
inclusion	  body	  myositis	  (IBM),	  non-­‐specific	  myositis	  (NSM)	  and	  immune-­‐mediated	  necrotizing	  myopathies	  (IMNM)	  [1].	  
The	  last	  subgroup	  constitutes	  a	  disorder	  with	  necrotic	  myofibres	  without	  significant	   inflammation	  as	  the	  predominant	  
abnormal	  histological	  feature	  [1].	  Necrotizing	  myopathies	  can	  also	  be	  secondary	  to	  drugs	  or	  associated	  with	  connective	  
tissue	  disorders	  or	  cancer	  [2].	  
The	  authors	  describe	  a	  case	  of	  a	  patient	  with	  necrotizing	  myopathy,	  thought	  to	  be	  immune	  mediated,	  highlighting	  the	  
challenge	  of	  its	  differential	  diagnosis.	  
	  
Case	  presentation	   	  
A	  66-­‐year-­‐old	  woman	  presented	  with	   a	   12-­‐month	   history	   of	   progressive	   symmetrical	   proximal	  muscle	  weakness	   and	  
discrete	  myalgia	   of	   the	  upper	   limbs.	   She	   complained	  of	   fatigue	  with	  progressive	  disability	   for	   daily	   routine	   activities.	  
Mild	  dysphagia	  was	  initially	  present,	  but	  did	  not	  persist.	  She	  reported	  none	  of	  the	  following:	  dermatologic	  alterations;	  
arthralgia;	  weight	  loss;	  eye,	  mouth	  and	  respiratory	  symptoms.	  The	  patient	  had	  a	  history	  of	  inguinal	  Hodgkin	  lymphoma	  
(mixed	   cellularity	   type,	   stage	   IIA)	   treated	  with	   chemo-­‐	   and	   radiotherapy	   and	   had	   been	   in	   complete	   remission	   for	   18	  
years.	  She	   reported	  no	   regular	  medication,	   including	   lipid-­‐lowering	  drugs,	  or	   toxic	  contact.	  No	   relevant	   family	  history	  
was	   reported.	   Physical	   examination	   showed	  proximal	  weakness	   in	   the	   arms	   (Medical	   Research	  Council	   grade	  3/5	   for	  
elbow	   flexion	   and	   extension	   and	   shoulder	   abduction)	   and	   legs	   (grade	   4/5	   for	   hip	   and	   knee	   flexion	   and	   extension);	  
sensory	  and	  skin	  examination	  was	  normal.	   	  
Laboratory	  tests	  showed	  elevated	  levels	  of	  creatine	  kinase	  (CK)	  (3509	  IU/l),	  myoglobin	  (829	  ng/ml),	  aldolase	  (47.2	  IU/l),	  
MB-­‐CK	   (125.7	   ng/ml)	   and	   lactate	   dehydrogenase	   (588	   IU/l).	   Serum	  aminotransferase	   levels	  were	   elevated	   (aspartate	  
transaminase/alanine	   transaminase	   81/133	   IU/l)	   and	   troponin	   I	   levels	  were	   normal.	   Serum	   creatinine	  was	   decreased	  
(0.37	   mg/dl);	   erythrocyte	   sedimentation	   rate	   (17	   mm/h)	   and	   C-­‐reactive	   protein	   CRP	   (0.10	   mg/dl)	   were	   normal.	   No	  
haemogram	   alterations	   or	   electrolyte	   imbalance	   were	   found.	   Thyroid	   and	   parathyroid	   hormones,	   thyroid	  
autoantibodies,	  HbA1c,	  complement,	  serum	  immunoglobulins	  and	  protein	  electrophoresis	  were	  normal.	  Testing	  for	  viral	  
and	  bacterial	  antibodies	  was	  negative	  (HIV,	  hepatitis	  B	  and	  C,	  herpes,	  Epstein–Barr	  virus,	  cytomegalovirus,	  Treponema	  
pallidum,	  Mycoplasma	  pneumoniae,	  zoonotic	  bacteria).	  Antinuclear	  antibodies	  (ANA)	  were	  moderately	  positive	  with	  a	  
fine	   dense	   granular	   pattern	   (1/160).	   Immunodiagnostic	   tests	   for	   myositis-­‐associated	   autoantibodies	   (MAA)	   and	  
myositis-­‐specific	   autoantibodies	   (MSA)	   were	   all	   negative	   (Table	   1)	   Electromyography	   showed	   spontaneous	   activity	  
(fibrillation	   potentials	   and	   positive	   sharp	  waves,	   complex	   repetitive	   discharges)	   in	   proximal	  muscles,	   consistent	  with	  
irritable	  myopathy.	  Nerve	   conduction	  was	   normal.	  Nail	   capillaroscopy,	   urine	   testing,	   oesophageal	  manometry,	   upper	  
endoscopy,	  echocardiogram,	   functional	   respiratory	   testing	  and	  thoracic-­‐abdominal-­‐pelvic	  CT	  scan	  showed	  no	  relevant	  
alterations.	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Autoantibody	  testing	   Result	  
Myositis-­‐associated	  autoantibodies	  (MAA)	  
Anti-­‐PM-­‐Scl	   negative	  
Anti-­‐RNP	   negative	  
Anti-­‐Ku	   negative	  
Anti-­‐Ro-­‐60	   negative	  
	   	  
Myositis-­‐specific	  autoantibodies	  (MSA)	  
Antisynthetase	  autoantibodies	  
Anti-­‐JO-­‐1	   negative	  
Anti-­‐PL-­‐7	   negative	  
Anti-­‐PL-­‐12	   negative	  
Anti-­‐EJ	   negative	  
Anti-­‐OJ	   negative	  
Nonsynthetase	  autoantibodies	  
Anti-­‐SRP	  (anti-­‐signal	  recognition	  particle)	   negative	  
Anti-­‐Mi-­‐2	   negative	  
Anti-­‐MDA5	   negative	  
Anti-­‐155/140	   negative	  
Anti-­‐SAE	   negative	  
Anti-­‐NXP2	   negative	  
Anti-­‐HMGCR	  (anti-­‐3-­‐hydroxy-­‐3-­‐methylglutaryl-­‐coenzyme	  A	  reductase)	   not	  available	  for	  routine	  testing	  
Other	  autoantibodies	   	  
All	  ANA	  (antinuclear	  autoantibodies)	   moderately	   positive	   with	   a	   fine	   dense	  
granular	  pattern	  (titre:	  1/160)	  
Anti-­‐ds-­‐DNA	   negative	  
Anti-­‐SS-­‐B	   negative	  
Anti-­‐Sm	   negative	  
Anti-­‐Scl70	   negative	  
Anti-­‐ANCA	  (anti-­‐neutrophil	  cytoplasmic	  autoantibodies)	   negative	  
Anti-­‐thyroglobulin	   negative	  





Table	  1:	  Patient	  autoantibody	  testing	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A	  left	  deltoid	  muscle	  biopsy	  was	  performed.	  Immunohistological	  examination	  demonstrated	  necrotic	  and	  regenerating	  
muscle	   fibres	   (Figs.	  1	  and	  2),	  discrete	   inflammatory	   infiltrate	   (Fig.	  2),	   strong	  MHC-­‐I	  expression	  on	  necrotic	   fibres	  and	  
mild	   expression	   on	   non-­‐necrotic	   ones	   (Fig.	   3).	   It	   also	   showed	   preserved	   dysferlin	   expression	   and	   no	   perifascicular	  
atrophy	  or	  vacuoles.	  
The	  patient	  was	  diagnosed	  with	  necrotizing	  myopathy	  and	  60	  mg/day	  of	  oral	  prednisolone	  (1	  mg/kg/day)	  was	  started	  
with	  a	  significant	  improvement	  in	  functional	  abilities	  and	  proximal	  muscle	  strength	  after	  2	  weeks.	  Corticosteroid	  doses	  
were	   tapered	   over	   a	   year,	   with	   sustained	   clinical	   and	   analytical	   improvement.	   Nearly	   normal	   CK	   and	   aldolase	   levels	  




	   	  
Figure	   1:	   Left	   deltoid	   muscle	   biopsy.	   Increased	   variability	   of	  
muscle	   fibre	   diameter	  with	   necrotic	   fibres	   (º)	   and	   regenerating	  
fibres	   with	   basophilic	   cytoplasm	   (*).	   Haematoxylin-­‐eosin	  
staining;	  ×200.	  
Figure	   2:	   Left	   deltoid	  muscle	   biopsy.	   Necrotic	   and	   regenerating	  
fibres,	   minimal	   inflammatory	   infiltrate	   (#).	   Hematoxylin-­‐eosin	  
staining;	  ×200.	  
	  
Figure	   1:	   Left	   deltoid	   muscle	   biopsy.	   Strong	   major	  
histocompatibility	  complex	  (MHC-­‐I)	  expression	  on	  necrotic	  fibres	  
(*)	   and	   mild	   expression	   on	   some	   non-­‐necrotic	   fibres.	   MHC-­‐I	  
immunoperoxidase	  staining,	  ×200.	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Discussion	  
IMNM	   are	   defined	   as	   ‘fulfilling	   clinical	   inclusion	   criteria	   of	   adult	   dermatomyositis	   or	   polymyositis,	   with	   subacute	   or	  
insidious	  post-­‐puberty	  onset	  of	   symmetric	  proximal	  >	  distal	   limb	  and	  neck	   flexor	  >	  neck	  extensor	  weakness,	  elevated	  
serum	  CK	  levels	  and	  detection	  of	  MSA,	  as	  well	  as	  exclusion	  criteria	  as	  IBM	  clinical	  features,	  dermatomyositis	  typical	  rash,	  
ocular	  weakness,	  isolated	  dysarthria	  and	  signs	  of	  toxic	  myopathy,	  endocrinopathy,	  family	  history	  of	  muscular	  dystrophy	  
or	   proximal	  motor	   neuropathies’.	  Many	   necrotic	  muscle	   fibres	   are	   considered	   the	   predominant	   histological	   feature;	  
inflammatory	  cells	  are	  sparse	  or	  slightly	  perivascular	  [1].	  IMNM	  have	  been	  misclassified	  in	  the	  past	  as	  dermatomyositis	  
or	  polymyositis	  [1].	  
As	   the	   patient	   presented	   muscle	   weakness	   and	   fatigue	   with	   elevated	   muscle	   enzymes,	   metabolic	   myopathies	   and	  
systemic	   inflammatory	  disease-­‐associated	  myopathies	  needed	  to	  be	  considered.	  The	  patient	  presented	  no	   joint,	   lung,	  
heart	   or	   renal	   involvement,	   and	   the	   inflammatory	   serum	   markers,	   hormonal,	   electrolyte	   and	   infection	   laboratory	  
parameters	  were	  normal.	  Despite	  the	  initial	  mild	  dysphagia,	  oesophageal	  manometry	  and	  upper	  endoscopy	  showed	  no	  
alterations.	  
As	   the	   patient	   fulfilled	   the	   clinical	   and	   laboratory	   criteria	   for	   an	   IIM,	   the	   differential	   diagnosis	   had	   to	   rely	   on	   skin	  
alterations	   and	   myopathological	   features	   [1].	   Dermatomyositis	   was	   ruled	   out	   by	   the	   absence	   of	   skin	   lesions,	  
perifascicular	  atrophy	  and	  significant	  perivascular	   inflammation.	  The	  pathological	  findings	  were	  also	  distinct	  from	  that	  
of	   polymyositis,	   as	   there	   was	   no	   significant	   endomysial	   infiltrate	   or	   ubiquitous	   MHC-­‐I	   expression.	   The	   absence	   of	  
rimmed	  vacuoles	  and	  ragged	  red	  fibres	  excluded	  IBM	  [1].	   	  
Some	  necrotizing	  myopathies	  can	  be	  drug	  induced	  [2].	  Although	  the	  patient	  presented	  clinicopathological	  features	  that	  
may	  suggest	  a	   toxic	  myopathy,	   there	  was	  no	  epidemiological	  context.	  There	  was	  no	  evidence	  of	  exogenous	  myotoxic	  
exposure,	  except	  when	  she	  was	  on	  Hodgkin	  lymphoma	  treatment,	  18	  years	  prior	  to	  myopathy	  onset.	  The	  time	  gap	  was	  
too	  wide	  to	  establish	  a	  cause–effect	  association,	  thus	  ruling	  out	  a	  drug-­‐induced	  aetiology.	  
Muscle	   fibre	   necrosis	   and	   regeneration	   with	   sparse	   inflammation	   is	   also	   observed	   in	   muscular	   dystrophy,	   but	   the	  
non-­‐prolonged	  clinical	  evolution,	  the	  absence	  of	  a	   family	  history	  of	  myopathy,	  the	  preserved	  dysferlin	  expression	  and	  
the	  early	  response	  to	  immunosuppressants	  ruled	  out	  the	  hypothesis	  of	  muscular	  dystrophy	  [2].	  
Paraneoplastic	  necrotizing	  myopathies	  share	  clinical,	  laboratory	  and	  pathological	  features	  with	  IMNM	  [2].	  An	  underlying	  
malignancy	   was	   excluded	   by	   the	   patient’s	   laboratory	   and	   diagnostic	   imaging	   evaluation,	   ruling	   out	   a	   paraneoplastic	  
framework.	  
Although	  many	  IMNM	  pathophysiological	  mechanisms	  are	  not	  entirely	  understood,	  the	  MSA	  identification	  suggests	  an	  
antibody-­‐mediated	   disease,	   in	  which	   antibodies	  may	   recruit	   cytotoxic	   immune	   effector	   cells	   via	   antibody-­‐dependent	  
cell-­‐mediated	  cytotoxicity.	  As	  the	  prominent	  histopathological	  feature	  of	  IMNM,	  necrosis	  translates	  a	  cytotoxic	  process.	  
Whether	  IMNM	  are	  directly	  triggered	  by	  unrecognized	  endogenous	  myotoxics	  or	  they	  are	  antibody-­‐mediated	  diseases	  
remains	  unclear	  [3].	  
Some	  MSA	  have	  been	  associated	  with	  IMNM:	  anti-­‐SRP	  and	  anti-­‐HMGCR	  [2,	  4,	  5].	  Usually,	  IMNM	  with	  positive	  anti-­‐SRP	  
autoantibodies	  has	  rapidly	  progressive	  disabling	  muscle	  weakness	  and	  is	  frequently	  associated	  with	  organ	  involvement	  
[2,	  4].	  Anti-­‐HMGCR	  autoantibodies	  have	  been	  identified	  in	  IMNM	  patients	  without	  a	  history	  of	  statin	  exposure	  [5].	  The	  
patient	  was	  not	  tested	  for	  anti-­‐HMGCR,	  as	  testing	  was	  not	  available.	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It	   has	   been	   reported	   that	   about	   50%	   of	   the	   IIM	   patients	   are	   autoantibody	   seronegative	   [6],	   implying	   that	   an	  
antibody-­‐mediated	   process	   is	   not	   an	   underlying	   pathophysiological	  mechanism	   of	   the	   disease.	   Although	   the	   patient	  
presented	  moderately	  positive	  ANA,	   these	  antibodies	  may	  be	  positive	   in	  healthy	   individuals,	   lacking	  diagnostic	  power	  
for	   autoimmune	   diseases.	   Despite	   the	   negative	   MAA	   and	   MSA	   testing,	   an	   immune-­‐mediated	   myopathic	   injury	   was	  
hypothesized	  for	  this	  patient	  and	  immunosuppressive	  treatment	  was	  considered	  suitable	  according	  to	  this	  hypothesis.	  
There	  was	  an	  effective	   therapeutic	   response,	  with	  clinical	  and	  analytical	   improvement	  after	  corticosteroid	   treatment,	  
strongly	  supporting	  the	  IMNM	  hypothesis.	  
Clinical	   assessment	   and	   diagnostic	   tools	   sometimes	   fail	   to	   determine	   whether	   a	   necrotizing	   myopathy	   is	   immune	  




• IMNM	   are	   recognized	   as	   a	   subgroup	   of	   idiopathic	   inflammatory	   myopathies	   along	   with	   dermatomyositis,	  
polymyositis,	  inclusion	  body	  myositis	  and	  non-­‐specific	  myositis.	  
• IMNM	   diagnosis	   is	   based	   on	   clinical	   features,	   laboratory	   studies	   (serum	   CK	   levels,	   electromyography,	   serum	  
myositis-­‐specific	   autoantibodies)	   and	   myopathological	   features.	   Prominent	   muscle	   fibre	   necrosis	   and	  
regeneration	  with	  minimal	  inflammatory	  infiltrate	  is	  the	  predominant	  abnormal	  histological	  feature.	  
• As	   clinical	   assessment	   and	   diagnostic	   tools	   sometimes	   fail	   to	   determine	   whether	   a	   necrotizing	   myopathy	   is	  
immune	   mediated,	   leading	   to	   misdiagnosis	   and	   a	   compromise	   of	   the	   optimal	   therapeutic	   approach,	  
distinguishing	   between	   IMNM	   and	   other	   myopathies	   is	   crucial.	   When	   there	   is	   no	   clear	   demonstration	   of	  
exogenous	  toxic	  contact	  and	  no	  other	  known	  aetiologies	  can	  be	  supported	  by	  evidence,	  even	  in	  the	  absence	  of	  
autoantibody	  seropositivity,	  an	  immunosuppressive	  treatment	  should	  be	  attempted	  based	  on	  the	  hypothesis	  of	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